RxDoctor Payments Data

Michael Delange, MD

Family Medicine · Layton, UTNPI 1043390958

Payments from drug & device makers

$4,221in general payments, 2019–2025

Across 233 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$494
  • AstraZeneca$423
  • Novo Nordisk$322
  • Lilly USA, LLC$296
  • Pfizer$258
  • GSK$240
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,221100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,221 in reported general payments places this provider in the 80th percentile of 928 family medicine providers in Utah.

See all family medicine providers in Utah

Medicare billing

Part B allowed, 2024
$113,729
Medicare patients
218
Services billed
3,356

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$67,004
EliquisApixaban50$50,143
MounjaroTirzepatide38$41,647
TrulicityDulaglutide35$40,872
JardianceEmpagliflozin22$30,870
XareltoRivaroxaban19$21,688
FarxigaDapagliflozin Propanediol24$20,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,869
RexultiBrexpiprazole11$15,383
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$14,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$7,737
Novolog FlexpenInsulin Aspart13$3,389
Gabapentin74$2,610
Atorvastatin Calcium274$2,406
Omeprazole126$2,342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$296$82,51973 claims
Novo NordiskOzempic$322$67,00454 claims
PfizerEliquis$258$50,14350 claims
Boehringer IngelheimJardiance$156$30,87022 claims
Johnson & JohnsonXarelto$128$21,68819 claims
AstraZenecaFarxiga$423$20,64424 claims
GSKTrelegy Ellipta$240$16,86920 claims
Otsuka America Pharmaceutical, Inc.Rexulti$186$15,38311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 928 family medicine providers in Utah.

Other family medicine in Layton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →